Featured Research

from universities, journals, and other organizations

Examination Of Widely Used Antimicrobial Compound Reveals New Strategies To Fight Malaria

Date:
December 23, 2008
Source:
Cell Press
Summary:
Scientists working on a common antimicrobial compound with antimalarial activity have discovered a range of new therapeutic strategies to combat malaria. The research, published in the journal Cell Host and Microbe, provides valuable insight into how the human malaria parasite's requirement for fatty acids can be exploited as it progresses through the distinct stages of its complex life cycle.

Scientists working on a common antimicrobial compound with antimalarial activity have discovered a range of new therapeutic strategies to combat malaria. The research, published by Cell Press in the December 11th issue of the journal Cell Host and Microbe, provides valuable insight into how the human malaria parasite's requirement for fatty acids can be exploited as it progresses through the distinct stages of its complex life cycle.

Infection with the human malaria parasite, Plasmodium falciparum, begins when an infected mosquito bites a human. Injected parasites migrate to the liver where they copy themselves inside liver cells and prepare to enter the bloodstream, invading red blood cells and initiating the blood stages that cause the clinical manifestations of the disease.

P. falciparum changes and proliferates rapidly during these life stages and requires an abundant source of fatty acid molecules to build new cell membranes. Blood stage parasites synthesize fatty acids using a type II fatty acid biosynthesis (FAS-II) pathway that is also employed by bacteria. FAS-II had been viewed as an excellent therapeutic target in parasites and bacteria as it is distinct from the type I (FAS-I) pathway used by mammals.

The FAS-II inhibitor triclosan has been widely used in antimicrobial creams, lotions and soaps and is often present as an additive in plastics, textiles and implantable medical devices. Earlier studies identified FabI, an enzyme in the FAS-II pathway, as the predicted target of triclosan in malaria parasites, propelling extensive research efforts to develop novel antimalarials based on this compound.

However, a new research study led by Dr. David A. Fidock from Columbia University showed that disruption of the FabI gene in P. falciparum or the rodent parasite P. berghei did not impede blood stage growth and that FabI was not the antimalarial target of triclosan. Fidock and colleagues also showed that triclosan was not as effective against the blood stage of the malaria parasite as was previously thought. "Although this enzyme has been extensively studied as a candidate drug target for blood stage malaria parasites, our data argue against the therapeutic potential of FabI, and indeed the entire FAS-II pathway, during infection of red blood cells," explains Dr. Fidock.

Nevertheless, Dr. Fidock and his colleagues went on to make an additional discovery. They demonstrated that an absence of FabI results in P. berghei parasites that, coming from the mosquito, are less infective and fail to complete the liver stage of development. These parasites are then typically unable to initiate the symptomatic blood stage infection. In contrast, during the blood stage, the parasites do not rely on FabI and appear to obtain fatty acids primarily by acquiring them from the host.

"We propose that therapeutic strategies to interfere with fatty acid processes in blood stage parasites should focus on scavenging these molecules taken from the host. This contrasts with liver stage parasites that depend on synthesizing their own fatty acids to meet their metabolic needs. Interference with FAS-II in liver stages now offers novel perspectives for prophylactic intervention," explains Dr. Fidock. "Our work also highlights the need for additional studies to elucidate how triclosan acts on blood stage parasites."


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Examination Of Widely Used Antimicrobial Compound Reveals New Strategies To Fight Malaria." ScienceDaily. ScienceDaily, 23 December 2008. <www.sciencedaily.com/releases/2008/12/081210121910.htm>.
Cell Press. (2008, December 23). Examination Of Widely Used Antimicrobial Compound Reveals New Strategies To Fight Malaria. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/12/081210121910.htm
Cell Press. "Examination Of Widely Used Antimicrobial Compound Reveals New Strategies To Fight Malaria." ScienceDaily. www.sciencedaily.com/releases/2008/12/081210121910.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins